If KUF-13046 confirms kinase inhibitory activity, it could enter preclinical panels for:
While many compounds in this category have been synthesized, KUF-13046 is distinguished by its specific structural scaffold and its potent, balanced affinity for both OX1R and OX2R. It was developed as part of research efforts to identify non-sedative anxiolytics (anti-anxiety medications) and hypnotics that minimize the side effects associated with current market standards. KUF-13046
To provide you with the detailed paper or information you need, could you please clarify the following? If KUF-13046 confirms kinase inhibitory activity, it could
represents a fascinating frontier in synthetic compound research—a molecule with plausible biological activity still awaiting full scientific validation. Its potential spans oncology, neuroinflammation, and chemical probe development. However, significant gaps remain: exact structure, confirmed mechanism, in vivo efficacy, and safety profile. and chemical probe development. However
Pour entrer, merci de confirmer que vous êtes un professionnel de santé